80岁以上患者的低剂量埃多克萨班:单中心真实世界分析
Ruiqi Zhang1, Jiali Du1, Meilin Liu2
1Department of Geriatrics, Peking University First Hospital, Beijing, 100034, People's Republic of China.
Drugs & aging
|September 13, 2025
概括
低剂量埃多克萨班 (15-30毫克) 在80岁及以上的患者中显示出良好的安全性和疗效. 这种方法需要对非常老年人群的个性化抗凝药进行仔细的风险评估.
科学领域:
- 心脏病学 心脏病学
- 老年病的医生 老年病的医生
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于高危的出血和血栓栓塞的高风险,八十岁人的抗凝血是复杂的.
- 在非常老年患者中,埃多克萨班的最佳剂量策略尚未确立.
研究的目的:
- 评估80岁及以上的患者减少剂量埃多克萨班 (每天15-30毫克) 的现实安全性和疗效.
- 为了在这个人群中比较不同降低剂量的edoxaban之间的结果.
主要方法:
- 在217名患者 (≥80岁) 接受edoxaban治疗的回顾性队列研究.
- 患者被分为两组:每天服用30毫克一次 (QD) 和15毫克QD.
- 结果包括抗Xa水平,出血事件,血栓形成,死亡率和生存分析.
主要成果:
- 服用15毫克的QD组年龄较大,估计的淋巴细胞过率 (eGFR) 和日常生活活动 (ADL) 分数较低.
- 与30毫克QD组 (0.56 ± 0.25 IU/mL) 相比,15毫克QD组 (0.35 ± 0.15 IU/mL) 的抗Xa峰值水平较低.
- 30毫克QD组的死亡率较低 (0.7%),而15毫克QD组的死亡率较低 (3.5%),出血和血栓形成的发病率相似.
结论:
- 低剂量埃多克萨班 (15-30毫克) 在非常老年患者中提供了有利的安全性和疗效.
- 个性化抗凝药需要对出血和缺血风险进行彻底评估.
- 进一步的研究可能会在老年人群中完善edoxaban的最佳剂量.
相关概念视频
01:15Drug Dosing: Geriatric Patients
199
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
199
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
172
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
172
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
214
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
214
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
200
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
200
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
201
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
201
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
176
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
176